Increasing Nevirapine Dose Can Overcome Reduced Bioavailability Due to Rifampicin Coadministration

We studied the effect of rifampicin on steady-state pharmacokinetics of nevirapine and the impact of increasing the dose of nevirapine on its peak (Cmax) and trough (Cmin) levels in 13 HIV-infected patients on regular antiretroviral treatment with nevirapine-containing regimens (200 mg twice daily)....

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Journal of acquired immune deficiency syndromes (1999) 2006-05, Vol.42 (1), p.36-41
Hauptverfasser:	Ramachandran, Geetha, Hemanthkumar, Agibothu K, Rajasekaran, Sigamani, Padmapriyadarsini, Chandrasekaran, Narendran, Gopalan, Sukumar, Baluswamy, Sathishnarayan, Srinivasan, Raja, Krishnaraj, Kumaraswami, Vasanthapuram, Swaminathan, Soumya
Format:	Artikel
Sprache:	eng
Schlagworte:	Administration, Oral Adult Anti-HIV Agents - administration & dosage Antibiotics, Antitubercular - administration & dosage Antibiotics, Antitubercular - blood Antibiotics, Antitubercular - pharmacokinetics Antiretroviral drugs Bioavailability Biological and medical sciences Drug Administration Schedule Drug dosages Drug Interactions Drug therapy Female Fundamental and applied biological sciences. Psychology HIV HIV Infections - complications HIV Infections - drug therapy HIV Infections - metabolism Human immunodeficiency virus Human viral diseases Humans India Infectious diseases Male Medical sciences Microbiology Middle Aged Miscellaneous Nevirapine - administration & dosage Nevirapine - blood Nevirapine - pharmacokinetics Reverse Transcriptase Inhibitors - administration & dosage Reverse Transcriptase Inhibitors - blood Reverse Transcriptase Inhibitors - metabolism Rifampin - administration & dosage Rifampin - blood Rifampin - pharmacokinetics Tuberculosis - complications Tuberculosis - drug therapy Viral diseases Virology
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	We studied the effect of rifampicin on steady-state pharmacokinetics of nevirapine and the impact of increasing the dose of nevirapine on its peak (Cmax) and trough (Cmin) levels in 13 HIV-infected patients on regular antiretroviral treatment with nevirapine-containing regimens (200 mg twice daily). A baseline pharmacokinetic study was conducted and repeated after 1 week of daily rifampicin (450/600 mg). The study was repeated in 7 of 8 patients who had subtherapeutic Cmin nevirapine levels after increasing nevirapine dose to 300 mg twice daily. Liver function was monitored. Rifampicin caused significant reductions in Cmax (42%), Cmin (53%), and exposure (46%) of nevirapine (P
ISSN:	1525-4135 1944-7884
DOI:	10.1097/01.qai.0000214808.75594.73